Precigen (NASDAQ:PGEN) Price Target Cut to $4.00

Precigen (NASDAQ:PGEN) had its price target decreased by HC Wainwright from $6.00 to $4.00 in a research report sent to investors on Thursday, Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Precigen’s FY2026 earnings at $0.02 EPS and FY2027 earnings at $0.24 EPS.

Other equities research analysts have also recently issued research reports about the stock. JMP Securities restated a market outperform rating and issued a $14.00 target price on shares of Precigen in a report on Tuesday, June 4th. StockNews.com upgraded shares of Precigen to a sell rating in a research report on Thursday, August 1st. Stifel Nicolaus increased their price target on shares of Precigen from $7.00 to $10.00 and gave the stock a buy rating in a research report on Monday, June 3rd. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Precigen in a research report on Wednesday, May 15th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Hold and an average target price of $7.00.

Precigen Trading Up 1.9 %

PGEN stock traded up $0.02 on Thursday, hitting $1.09. The company had a trading volume of 400,983 shares, compared to its average volume of 1,029,246. Precigen has a 12-month low of $0.84 and a 12-month high of $1.93. The stock’s 50-day simple moving average is $1.52 and its 200 day simple moving average is $1.46. The stock has a market cap of $275.14 million, a price-to-earnings ratio of -2.74 and a beta of 1.73.

Precigen (NASDAQ:PGEN) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Precigen had a negative return on equity of 76.35% and a negative net margin of 3,084.55%. The company had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.54 million. During the same quarter in the prior year, the business posted ($0.10) EPS. Research analysts forecast that Precigen will post -0.38 earnings per share for the current year.

Insider Activity

In other news, SVP Jeffrey Thomas Perez acquired 58,823 shares of the firm’s stock in a transaction dated Friday, August 9th. The shares were purchased at an average cost of $0.85 per share, for a total transaction of $49,999.55. Following the transaction, the senior vice president now directly owns 743,097 shares of the company’s stock, valued at $631,632.45. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 44.90% of the company’s stock.

Institutional Trading of Precigen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Patient Capital Management LLC increased its holdings in Precigen by 16.2% in the 4th quarter. Patient Capital Management LLC now owns 15,983,700 shares of the biotechnology company’s stock valued at $21,418,000 after acquiring an additional 2,230,524 shares during the last quarter. Sanders Morris Harris LLC purchased a new position in shares of Precigen in the 1st quarter worth $1,022,000. Opaleye Management Inc. grew its stake in shares of Precigen by 9.0% in the 4th quarter. Opaleye Management Inc. now owns 1,012,500 shares of the biotechnology company’s stock worth $1,357,000 after buying an additional 84,000 shares in the last quarter. Panagora Asset Management Inc. purchased a new position in shares of Precigen in the 4th quarter worth $407,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Precigen in the 1st quarter worth $31,000. 33.51% of the stock is currently owned by institutional investors.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.